Monitor for 10b5-1 plan disclosures in upcoming filings; consider this a caution signal ahead of earnings or clinical updates. Absence of offsetting buy signals increases downside risk.
ARQT drugs
ARQT drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $24.76entry
- T+1 · 9mo ago −4.68%α −3.77% · $23.60
- T+5 · 8mo ago +0.24%α +1.45% · $24.82
- T+20 · 8mo ago −13.85%α −5.91% · $21.33
- T+60 · 6mo ago −14.74%α −24.07% · $21.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple insiders at Arcutis Biotherapeutics sold shares in a coordinated open-market cluster totaling $1.65M over two days, including CFO Latha Vairavan. These sales coincide with routine stock award grants, suggesting pre-arranged 10b5-1 plans. The total value represents 0.06% of market cap, modest but notable due to C-suite participation.
Key Financial Metrics
Key Facts
- Seven open-market sales totaling $1.65M occurred on March 2, 2026, by five insiders including CFO Latha Vairavan.
- Concurrent with sales, five insiders received non-cash stock grants totaling 226,000 shares ($0 value).
- Sales represent ~0.06% of $2.9B market cap, not large in absolute terms but concentrated among executives.
- All transactions occurred within a 7-day window, indicating coordinated timing, likely under 10b5-1 plans.
Financial Impact
$1.65 million in insider selling, offset by $0 in non-cash grants
Risk Factors
- Perception of insider pessimism despite likely pre-arranged trades
- Potential for follow-on selling if 10b5-1 plans are ongoing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (11 trades, 7d window) | cluster-ARQT-1772659026262 |
Track record
34 reports on ARQT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers